PROTECT-COG: $100M global trial combining lifestyle + GLP-1 for dementia prevention
Key Questions
What is the PROTECT-COG study?
PROTECT-COG is a $100M global trial launched by the Alzheimer's Association that combines the U.S. POINTER lifestyle intervention with GLP-1 drugs to prevent cognitive decline and dementia. It was announced at AAIC 2026 and builds on evidence from both lifestyle and pharmacological approaches.
How does PROTECT-COG integrate lifestyle changes with GLP-1 medications?
The trial merges the structured lifestyle program from U.S. POINTER with GLP-1 or similar drugs to evaluate their combined impact on reducing Alzheimer's risk. Recruitment and design details are still emerging.
What is the goal of the PROTECT-COG trial?
The goal is to test whether combining lifestyle interventions with GLP-1 drugs can cut the risk of cognitive decline more effectively than either approach alone. It represents a major prevention science initiative supported by the Alzheimer's Association.
Alzheimer's Association launched PROTECT-COG, a $100M global trial merging the U.S. POINTER lifestyle intervention with GLP-1 drugs. Announced at AAIC 2026, it builds on strong evidence from both domains and represents a bold prevention science initiative. Recruitment and design details are emerging.